Skip to main content
SleepCited

Melatonin for primary insomnia?

Review Drug and therapeutics bulletin 2009
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'pmid\u003D19567841'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Çalışma Türü
Review
Popülasyon
None
Müdahale
Melatonin for primary insomnia? None
Karşılaştırıcı
None
Birincil Sonuç
Melatonin for primary insomnia?
Etki Yönü
Mixed
Yanlılık Riski
Unclear

Abstract

Melatonin, a hormone produced by the pineal gland, has a key role in regulating circadian rhythms, most importantly, the sleep-wake cycle. Melatonin's action has led to its being tried as a treatment for a wide range of sleep disorders, such as jet lag, primary insomnia, sleep-wake cycle disruption and sleep problems in children with neuro-developmental disorders. Until recently, it had not been licensed in the UK for any indication. Prolonged-release melatonin (Circadin - Lundbeck) has now been licensed as a treatment for primary insomnia. Here we consider whether this product has a place in the management of people with this condition.

Kısaca

Prolonged-release melatonin (▼Circadin – Lundbeck) has now been licensed as a treatment for primary insomnia and it is considered whether this product has a place in the management of people with this condition.

Used In Evidence Reviews

Similar Papers